Oramed Pharmaceuticals Inc (ORMP) Stock Analysis

Oramed Pharmaceuticals Inc (ORMP) is a publicly traded company in the HEALTHCARE sector. It trades at $3.60, carries a market capitalization of $159.20M, a price-to-earnings ratio of 1.50. This page summarizes the public market data, fundamentals, and frequently asked questions for ORMP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Oramed Pharmaceuticals Inc currently has a Bullish sentiment score of 0.30.

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. is a groundbreaking biopharmaceutical company based in New York, focused on transforming diabetes management with its novel oral drug delivery systems. The company specializes in developing orally ingestible capsules for the administration of polypeptides, designed to improve patient adherence and outcomes in diabetes care. With a robust pipeline of innovative therapeutic solutions and a dedication to addressing critical unmet medical needs, Oramed is strategically...

GNG Research Analysis

GNG Research scores Oramed Pharmaceuticals Inc (ORMP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ORMP.

Frequently Asked Questions

Does ORMP pay dividends?

Oramed Pharmaceuticals Inc (ORMP) does not currently pay a regular dividend.

What is ORMP's P/E ratio?

Oramed Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 1.50.

What is ORMP's market cap?

Oramed Pharmaceuticals Inc (ORMP) has a market capitalization of $159.20M with a current stock price of $3.60.